Alemtuzumab for Multiple Sclerosis

Alemtuzumab is a humanised anti-CD52 monoclonal antibody approved for use in active, relapsing multiple sclerosis (MS). Administration results in a rapid depletion of circulating lymphocytes with a subsequent beneficial immune reconstitution. Early open-label experience and recent clinical trials ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Willis, Mark D., Robertson, Neil P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Demyelinating Disorders (DN Bourdette and M Cameron, Section Editors)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971037/
https://www.ncbi.nlm.nih.gov/pubmed/27485945
http://dx.doi.org/10.1007/s11910-016-0685-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971037/
https://www.ncbi.nlm.nih.gov/pubmed/27485945
http://dx.doi.org/10.1007/s11910-016-0685-y

Ejemplares similares